FAM162A may serve as possible therapeutic and diagnostic targets for human dilated and ischemic cardiomyopathies because it was differentially expressed at the transcriptomic and proteomic levels in a number of rodent and human heart disease models (Lee et al., 2020). This evidence concerns the gene FAM162A and ischemic cardiomyopathy.